| 2026-03-09 | 10-K | 10.22 | License and Collaboration Agreement, dated as of October 16, 2025, by and between Dianthus Therapeutics, Inc. and Nanjing Leads Biolabs Co. Ltd. |
|---|
| 2026-03-09 | 10-K | 10.21 | Dianthus Therapeutics, Inc. Equity Inducement Plan (Amended and Restated on December 17, 2025). |
|---|
| 2024-08-08 | 10-Q | 10.1 | Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended. |
|---|
| 2024-05-28 | 8-K | 10.1 | Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan |
|---|
| 2024-03-21 | 10-K | 10.22 | Separation Agreement, dated September 11, 2023, by and between Magenta Therapeutics, Inc. and Thomas Beetham. |
|---|
| 2024-03-21 | 10-K | 10.20 | Separation Agreement, dated May 12, 2023, by and between Magenta Therapeutics, Inc. and Lisa Olson. |
|---|
| 2024-03-21 | 10-K | 10.19 | Separation Agreement, dated February 7, 2023, by and between Magenta Therapeutics, Inc. and Jason Gardner. |
|---|
| 2024-03-21 | 10-K | 10.15 | Amendment to Offer Letter, dated September 11, 2023, by and between Dianthus Therapeutics OpCo, Inc. and Simrat Randhawa. |
|---|
| 2024-03-21 | 10-K | 10.8 | Form of Stock Option Agreement for Executives under the Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan. |
|---|
| 2024-03-21 | 10-K | 10.6 | Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan. |
|---|
| 2024-01-22 | 8-K | 10.2 | Form of Registration Rights Agreement. |
|---|
| 2024-01-22 | 8-K | 10.1 | Securities Purchase Agreement, dated January 22, 2024, by and between Dianthus Therapeutics, Inc. and each purchaser identified on Annex A thereto. |
|---|
| 2023-11-09 | 10-Q | 10.12 | Separation Agreement, dated September 11, 2023, by and between Magenta Therapeutics, Inc. and Stephen Mahoney. |
|---|
| 2023-09-12 | 8-K | 10.7 | Amendment to Offer Letter, dated September 11, 2023, by and between OpCo and Edward Carr. |
|---|
| 2023-09-12 | 8-K | 10.6 | Amendment to Offer Letter, dated September 11, 2023, by and between OpCo and Ryan Savitz. |
|---|
| 2023-09-12 | 8-K | 10.5 | Amendment to Offer Letter, dated September 11, 2023, by and between OpCo and Marino Garcia. |
|---|
| 2023-09-12 | 8-K | 10.4 | Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan. |
|---|
| 2023-09-12 | 8-K | 10.3 | Form of Indemnification Agreements for Officers of the Company. |
|---|
| 2023-09-12 | 8-K | 10.2 | Form of Indemnification Agreements for Directors of the Company. |
|---|
| 2023-09-12 | 8-K | 10.1 | Contingent Value Rights Agreement, dated September 11, 2023, by and between the Company and the Rights Agent. |
|---|
| 2023-05-03 | 8-K | 10.4 | Form of Contingent Value Rights Agreement |
|---|
| 2023-05-03 | 8-K | 10.3 | Form of Lock-Up Agreement |
|---|
| 2023-05-03 | 8-K | 10.2 | Form of Magenta Support Agreement |
|---|
| 2023-05-03 | 8-K | 10.1 | Form of Dianthus Support Agreement |
|---|
| 2023-03-23 | 10-K | 10.11 | Amended and Restated Employment Agreement by and between the Registrant and Lisa Olson, effective May 2, 2022. |
|---|
| 2023-03-23 | 10-K | 10.10 | Amended and Restated Employment Agreement by and between the Registrant and Jeffrey Humphrey, effective May 2, 2022. |
|---|
| 2022-11-03 | 10-Q | 10.1 | Amendment No. 3, effective as of August 1, 2022, to the Exclusive Research, Development Option and License Agreement by and between the Registrant and Heidelberg Pharma Research GmbH, dated as of March 1, 2018. |
|---|
| 2022-05-02 | 8-K | 10.2 | Amended and Restated Employment Agreement by and between the Registrant and David Nichols, effective May 2, 2022. |
|---|
| 2022-05-02 | 8-K | 10.1 | Amended and Restated Employment Agreement by and between the Registrant and Thomas Beetham, effective May 2, 2022. |
|---|
| 2022-03-08 | 10-K | 10.13 | Amended and Restated Employment Agreement by and between the Registrant and Stephen Mahoney, effective March 3, 2022. |
|---|
| 2022-03-08 | 10-K | 10.12 | Amended and Restated Employment Agreement by and between the Registrant and Jason Gardner, effective March 3, 2022. |
|---|
| 2022-03-08 | 10-K | 10.11 | Master Services Agreement, dated as of May 22, 2019, by and between the Registrant and Heidelberg Pharma Research GmbH. |
|---|
| 2021-05-12 | 8-K | 10.1 | Securities Purchase Agreement, dated as of May 12, 2021, among Magenta Therapeutics, Inc. and each purchaser party thereto. |
|---|
| 2021-05-06 | 10-Q | 10.1 | Employment Agreement by and between the Registrant and Stephen F. Mahoney, effective November 9, 2020. |
|---|
| 2021-03-03 | 10-K | 10.14.2 | Second Amendment to Sublease Agreement, dated as of August 19, 2020, by and between the Registrant and Novartis Institutes for BioMedical Research, Inc. |
|---|
| 2021-03-03 | 10-K | 10.10.7 | Amendment #1 to Collaboration Agreement, effective as of December 31, 2020, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program d/b/a Be The Match BioTherapies, dated as of November 10, 2017. |
|---|
| 2021-03-03 | 10-K | 10.10.5 | Amendment #3 to Project Rider #1, effective as of December 16, 2020, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program d/b/a Be The Match BioTherapies, dated as of November 10, 2017. |
|---|
| 2021-03-03 | 10-K | 10.10.4 | Amendment #2 to Project Rider #1, effective as of November 13, 2019, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program d/b/a Be The Match BioTherapies, dated as of November 10, 2017. |
|---|
| 2020-11-05 | 10-Q | 10.1 | First Amendment to Employment Agreement, executed as of October 14, 2020, by and between the Registrant and John C. Davis, Jr., M.D. |
|---|
| 2019-11-13 | 10-Q | 10.2 | Amendment, effective as of July 4, 2019, pursuant to the Exclusive Research, Development Option and License Agreement by and between the Registrant and Heidelberg Pharma Research GmbH, dated as of March 1, 2018. |
|---|
| 2019-11-13 | 10-Q | 10.1 | Amendment #1 to Project Rider #3, effective as of August 26, 2019, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program d/b/a Be The Match BioTherapies, dated as of November 10, 2017. |
|---|
| 2019-06-11 | 8-K | 10.1 | 2019 Employee Stock Purchase Plan |
|---|
| 2019-03-19 | 10-K | 10.9.3 | Amendment #1 to Project Rider #1, effective as of December 6, 2018, pursuant to the Collaboration Agreement by and between the Registrant and Be The Match BioTherapies, dated as of November 10, 2017. |
|---|
| 2019-03-19 | 10-K | 10.9.2 | Project Rider #3, effective as of September 6, 2018, pursuant to the Collaboration Agreement by and between the Registrant and Be The Match BioTherapies, dated as of November 10, 2017. |
|---|
| 2019-03-19 | 10-K | 10.9.1 | Project Rider #2, effective as of June 26, 2018, pursuant to the Collaboration Agreement by and between the Registrant and Be The Match BioTherapies, dated as of November 10, 2017. |
|---|
| 2018-11-08 | 10-Q | 10.1 | Agreement, dated as of May 31, 2018, by and between the Registrant and The Richmond Group, Inc. |
|---|